244 related articles for article (PubMed ID: 25155401)
1. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy.
Luo G; Guo M; Liu Z; Xiao Z; Jin K; Long J; Liu L; Liu C; Xu J; Ni Q; Yu X
Ann Surg Oncol; 2015 Feb; 22(2):670-6. PubMed ID: 25155401
[TBL] [Abstract][Full Text] [Related]
2. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
[TBL] [Abstract][Full Text] [Related]
3. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
Chen Y; Yan H; Wang Y; Shi Y; Dai G
Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
[TBL] [Abstract][Full Text] [Related]
4. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Neutrophil-to-Lymphocyte Ratio as a Predictor of Long-Term Prognosis after Pancreatectomy for Pancreatic Carcinoma: A Retrospective Analysis.
Tsujita E; Ikeda Y; Kinjo N; Yamashita YI; Hisano T; Furukawa M; Taguchi KI; Morita M; Toh Y; Okamura T
Am Surg; 2017 Jun; 83(6):610-616. PubMed ID: 28637563
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
8. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
[TBL] [Abstract][Full Text] [Related]
9. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
10. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
[TBL] [Abstract][Full Text] [Related]
12. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Okamura Y
Ann Surg Oncol; 2013 Dec; 20(13):4330-7. PubMed ID: 23982254
[TBL] [Abstract][Full Text] [Related]
13. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
Guo J; Wu M; Guo L; Zuo Q
Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
[TBL] [Abstract][Full Text] [Related]
19. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
20. The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction.
Yuan D; Zhu K; Li K; Yan R; Jia Y; Dang C
J Surg Oncol; 2014 Sep; 110(3):333-40. PubMed ID: 24889121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]